PBIGF Paradigm Biopharmaceuticals Ltd. Forecast, Technical & Fundamental Analysis

Momentum Indicator for PBIGF turns positive, indicating new upward trend

PBIGF saw its Momentum Indicator move above the 0 level on September 18, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator turned positive. In of the 35 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PBIGF's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBIGF just turned positive on September 16, 2025. Looking at past instances where PBIGF's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .

PBIGF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for PBIGF moved below the 200-day moving average on August 20, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

The Aroon Indicator for PBIGF entered a downward trend on September 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PBIGF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.394) is normal, around the industry mean (19.714). P/E Ratio (0.000) is within average values for comparable stocks, (54.201). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.145). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (1666.667) is also within normal values, averaging (346.197).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBIGF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.